Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN (NYSE: QGEN) has launched the artus® SARS-CoV-2 Prep&Amp UM Kit, enhancing COVID-19 testing efficiency through liquid-based sample preparation. This kit, now CE-IVD registered in the EU and under EUA review by the FDA, supports up to 672 samples in eight hours, reducing waste and time compared to standard methods. QIAGEN aims to increase testing capacity amidst ongoing COVID-19 cases, showcasing a versatile technology applicable beyond the pandemic. The company continues to expand its comprehensive SARS-CoV-2 testing solutions.
QIAGEN N.V. (NYSE: QGEN) announced its first quarter 2021 results will be released on May 3, 2021, at approximately 22:05 CET / 16:05 EDT. A conference call, hosted by CEO Thierry Bernard and CFO Roland Sackers, is scheduled for May 4, 2021, at 15:00 CET / 9:00 EDT. Interested parties can join via phone or access the webcast. The company is a leader in providing Sample to Insight solutions, serving over 500,000 customers globally in Molecular Diagnostics and Life Sciences. More details can be found through their contact at IR@qiagen.com.
QIAGEN N.V. (NYSE:QGEN) has launched the QIAseq DIRECT SARS-CoV-2 Kit, enhancing the efficiency of viral genome sequencing. This innovative kit reduces library preparation time to as little as four hours and decreases plastic use by 50%. It can multiplex up to 768 samples, improving throughput significantly. The kit is integrated with the QIAGEN Digital Insights CoV-2 Insights Service, designed for analyzing large viral datasets. This launch is a strategic expansion of QIAGEN’s portfolio, bolstering its position in the ongoing COVID-19 pandemic response.
QIAGEN N.V. (NYSE: QGEN) has received Emergency Use Authorization from the U.S. FDA for its NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay. This multiplex PCR test enables rapid identification and differentiation of respiratory viral infections, critical during the COVID-19 pandemic. With a processing time of 80 minutes, the test targets influenzas A and B, RSV, and SARS-CoV-2. The test, initially launched in the EU in 2020, enhances QIAGEN's diagnostics portfolio, supporting healthcare providers as respiratory infections increase.
QIAGEN N.V. (NYSE: QGEN) has filed its annual report for the year ending December 31, 2020, with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible via QIAGEN's website. The company specializes in Sample to Insight solutions, aiding over 500,000 global customers in molecular diagnostics and life sciences. As of the end of 2020, QIAGEN had over 5,600 employees in more than 35 locations worldwide. For further details, refer to their official site.
QIAGEN has launched the QIAsphere cloud-based platform, enabling labs and QIAstat-Dx users to monitor testing and instrument status continuously. This platform enhances syndromic testing by providing real-time visibility across multiple instruments, thereby reducing downtime and improving efficiency. QIAsphere will also allow technical service teams to offer rapid support. Initially marketed for the QIAcube Connect platform, it will soon extend to other molecular diagnostics solutions. This innovation is expected to bring molecular testing closer to patients.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched the QIAcube Connect MDx, an automated sample processing platform for molecular diagnostic labs in the U.S., Canada, and the EU. This enhanced instrument supports in-vitro diagnostic applications and is compatible with over 80 QIAGEN kits. With over 9,800 QIAcube instruments deployed by end of 2020, this new version follows strict medical device standards, improving lab safety and workflow efficiency. It automates the processing of SARS-CoV-2 and other viral samples, standardizing multiple sample purification.
INOVIO Pharmaceuticals (NASDAQ: INO) and QIAGEN (NYSE: QGEN) have extended their partnership to develop liquid biopsy-based companion diagnostics utilizing next-generation sequencing (NGS) technology. This collaboration focuses on a diagnostic test to identify women likely to benefit from INOVIO's VGX-3100, an immunotherapy for advanced cervical dysplasia linked to HPV. VGX-3100 is currently undergoing two Phase 3 trials, aiming to be the first non-surgical treatment for this condition. QIAGEN's expertise in bioinformatics will enhance the predictive capability of the diagnostic test.
QIAGEN and INOVIO Pharmaceuticals have extended their partnership with a master collaboration agreement to develop liquid biopsy-based diagnostic products utilizing next-generation sequencing (NGS) technology. The initial project will focus on a diagnostic test for identifying women who may benefit from VGX-3100, INOVIO's immunotherapy for advanced cervical dysplasia linked to HPV. This test will leverage QIAGEN’s bioinformatics to enhance INOVIO’s biomarker signature and will be developed for the Illumina NextSeq 550Dx platform, following a partnership established in 2019.
QIAGEN has appointed Thomas Ebeling to its Supervisory Board, effective immediately. Ebeling, with a robust background in healthcare and management, previously served as CEO of ProSiebenSat.1 Media and held significant roles at Novartis. This addition expands the Board to eight members, enhancing its expertise in Life Sciences and diagnostics. Lawrence Rosen, Chairman of the Supervisory Board, emphasized the commitment to corporate governance and value creation for stakeholders.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
